精彩内容近日,四川大学华西第四医院发布公告,将引进48款新药以满足临床用药需求,“中化生”领域均有涉及。其中,独家品种(含剂型独家,下同)占比超45%;从一级集团上看,正大制药、科伦、恒瑞等各有2个产品在列。48款进院新药包含35款化药、9款生物药和4款中成药;从剂型上看,注射剂和片剂为主力军,各占19个和16个席位;按治疗大类统计,抗肿瘤和免疫调节剂、神经系统药物均以11个产品在数量上领跑;一级...
Source Link精彩内容近日,四川大学华西第四医院发布公告,将引进48款新药以满足临床用药需求,“中化生”领域均有涉及。其中,独家品种(含剂型独家,下同)占比超45%;从一级集团上看,正大制药、科伦、恒瑞等各有2个产品在列。48款进院新药包含35款化药、9款生物药和4款中成药;从剂型上看,注射剂和片剂为主力军,各占19个和16个席位;按治疗大类统计,抗肿瘤和免疫调节剂、神经系统药物均以11个产品在数量上领跑;一级...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.